Literature DB >> 10527663

The structural basis of phenylketonuria.

H Erlandsen1, R C Stevens.   

Abstract

The human phenylalanine hydroxylase gene (PAH) (locus on human chromosome 12q24.1) contains the expressed nucleotide sequence which encodes the hepatic enzyme phenylalanine hydroxylase (PheOH). The PheOH enzyme hydroxylates the essential amino acid l-phenylalanine resulting in another amino acid, tyrosine. This is the major pathway for catabolizing dietary l-phenylalanine and accounts for approximately 75% of the disposal of this amino acid. The autosomal recessive disease phenylketonuria (PKU) is the result of a deficiency of PheOH enzymatic activity due to mutations in the PAH gene. Of the mutant alleles that cause hyperphenylalaninemia or PKU 99% map to the PAH gene. The remaining 1% maps to several genes that encode enzymes involved in the biosynthesis or regeneration of the cofactor ((6R)-l-erythro-5,6,7,8-tetrahydrobiopterin) regenerating the cofactor (tetrahydrobiopterin) necessary for the hydroxylation reaction. The recently solved crystal structures of human phenylalanine hydroxylase provide a structural scaffold for explaining the effects of some of the mutations in the PAH gene and suggest future biochemical studies that may increase our understanding of the PKU mutations. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10527663     DOI: 10.1006/mgme.1999.2922

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  33 in total

1.  Protein stability and in vivo concentration of missense mutations in phenylalanine hydroxylase.

Authors:  Zhen Shi; Jenn Sellers; John Moult
Journal:  Proteins       Date:  2011-09-21

2.  Missense mutations in the N-terminal domain of human phenylalanine hydroxylase interfere with binding of regulatory phenylalanine.

Authors:  T Gjetting; M Petersen; P Guldberg; F Güttler
Journal:  Am J Hum Genet       Date:  2001-04-20       Impact factor: 11.025

3.  Computational study of missense mutations in phenylalanine hydroxylase.

Authors:  Kamila Réblová; Petr Kulhánek; Lenka Fajkusová
Journal:  J Mol Model       Date:  2015-03-07       Impact factor: 1.810

Review 4.  A structural hypothesis for BH4 responsiveness in patients with mild forms of hyperphenylalaninaemia and phenylketonuria.

Authors:  H Erlandsen; R C Stevens
Journal:  J Inherit Metab Dis       Date:  2001-04       Impact factor: 4.982

Review 5.  Garrod's foresight; our hindsight.

Authors:  C R Scriver
Journal:  J Inherit Metab Dis       Date:  2001-04       Impact factor: 4.982

Review 6.  What we know that could influence future treatment of phenylketonuria.

Authors:  C N Sarkissian; A Gámez; C R Scriver
Journal:  J Inherit Metab Dis       Date:  2008-08-03       Impact factor: 4.982

7.  Phenylketonuria: an inborn error of phenylalanine metabolism.

Authors:  Robin A Williams; Cyril D S Mamotte; John R Burnett
Journal:  Clin Biochem Rev       Date:  2008-02

8.  Simulations of the regulatory ACT domain of human phenylalanine hydroxylase (PAH) unveil its mechanism of phenylalanine binding.

Authors:  Yunhui Ge; Elias Borne; Shannon Stewart; Michael R Hansen; Emilia C Arturo; Eileen K Jaffe; Vincent A Voelz
Journal:  J Biol Chem       Date:  2018-10-04       Impact factor: 5.157

9.  Genotype-phenotype correlations analysis of mutations in the phenylalanine hydroxylase (PAH) gene.

Authors:  Dani Bercovich; Arava Elimelech; Joel Zlotogora; Sigal Korem; Tal Yardeni; Nurit Gal; Nurit Goldstein; Bela Vilensky; Roni Segev; Smadar Avraham; Ron Loewenthal; Gerard Schwartz; Yair Anikster
Journal:  J Hum Genet       Date:  2008-02-26       Impact factor: 3.172

10.  The Missense p.S231F phenylalanine hydroxylase gene mutation causes complete loss of enzymatic activity in vitro.

Authors:  Maja Stojiljkovic; Belén Pérez; Lourdes R Desviat; Cristina Aguado; Magdalena Ugarte; Sonja Pavlovic
Journal:  Protein J       Date:  2009-08       Impact factor: 2.371

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.